FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Avoiding FDA Warning Letters: Why High Level Biodecontamination Is Essential in Pharma Manufacturing The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies